Zahra Shahsavar Haghighi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zahra Shahsavar Haghighi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Arezoo Farhadi
Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2 shared publications - Javad Behroozi
Cancer Epidemiology Research Center, Aja University of Medical Sciences, Tehran, Iran
2 shared publications - Mohammad Foad Heidari
Department of Medical Laboratory Sciences, School of Allied Health Medicine, AJA University of Medical Sciences, Tehran, Iran
2 shared publications - Reza Heidari
Medical Biotechnology Research Center, AJA University of Medical Sciences, Tehran, Iran
2 shared publications - Sara Rafi Taheri
Department of Genetics and Biotechnology, Faculty of Life Science, Varamin- Pishva Branch, Islamic Azad University, Varamin, Iran
2 shared publications A. Hekmatdoust
Department of Obstetrics and Gynecology, Tehran University of Medical Sciences, Mirza-Koochak-Khan Hospital, Tehran, Iran
1 shared publication
Latest Publications
- 1 May 2024
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 29 (2) , 24-37
Evaluation of DPT Metastasis Suppressor Gene Expression in Human Gastric Cancer
- 1 May 2024
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 29 (2) , 24-37
Evaluation of DPT Metastasis Suppressor Gene Expression in Human Gastric Cancer
- Open Access
- 1 May 2023
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 45 (2) , 117-129
Evaluation of the TXNIP gene expression in gastric adenocarcinoma and its relationship with overall survival of patients
Background. Gastric Cancer (GC) is a common gastrointestinal tumor, and its incidence is increasing. The pathogenesis of GC is very complex and remains unclear. Recent basic studies of GC have focused on gene expression dysregulation. Accumulating evidence has demonstrated that thioredoxin-interacting protein (TXNIP) is abnormally expressed in a variety of malignant tumors but it is obscure in GC. This study aimed to compare the expression of the TXNIP gene in cancerous and adjacent tissue of gastric cancer and evaluate its clinical significance in the prognosis and survival analysis of gastric cancer patients. Methods. A total of 50 tumor tissues and marginal non-tumor control tissues were obtained from GC patients. Also, TXNIP gene expression levels were evaluated by real-time PCR. Meanwhile, bioinformatic approaches were used to evaluate TXNIP expression in two different cohorts of GC patients. A data mining study was also performed to determine the prognostic role of TXNIP expression in the overall survival of GC. Furthermore, a pan-cancer analysis of TXNIP expression was performed using TCGA data. Results. The TXNIP gene was down-regulated in tumor samples with a fold change of 0.33, and the same results were repeated in bioinformatics analysis. Decreased expression of TXNIP was significantly associated with metastasis, poor differentiation, and drug abuse. Our results provided evidence that TXNIP gene expression level is positively correlated with the overall survival of GC patients. Pan-cancer analysis of TCGA data revealed down-regulated TXNIP in a variety of malignant tumors. Conclusion. This study established low TXNIP expression as a prognostic biomarker in GC. It also revealed that the decrease in TXNIP expression likely favors metastatic GC. Practical Implications. Evaluation of TXNIP expression is informative in the prognosis of GC patients.
- 1 May 2023
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 45 (2) , 117-129
Open AccessEvaluation of the TXNIP gene expression in gastric adenocarcinoma and its relationship with overall survival of patients
Background. Gastric Cancer (GC) is a common gastrointestinal tumor, and its incidence is increasing. The pathogenesis of GC is very complex and remains unclear. Recent basic studies of GC have focused on gene expression dysregulation. Accumulating evidence has demonstrated that thioredoxin-interacting protein (TXNIP) is abnormally expressed in a variety of malignant tumors but it is obscure in GC. This study aimed to compare the expression of the TXNIP gene in cancerous and adjacent tissue of gastric cancer and evaluate its clinical significance in the prognosis and survival analysis of gastric cancer patients. Methods. A total of 50 tumor tissues and marginal non-tumor control tissues were obtained from GC patients. Also, TXNIP gene expression levels were evaluated by real-time PCR. Meanwhile, bioinformatic approaches were used to evaluate TXNIP expression in two different cohorts of GC patients. A data mining study was also performed to determine the prognostic role of TXNIP expression in the overall survival of GC. Furthermore, a pan-cancer analysis of TXNIP expression was performed using TCGA data. Results. The TXNIP gene was down-regulated in tumor samples with a fold change of 0.33, and the same results were repeated in bioinformatics analysis. Decreased expression of TXNIP was significantly associated with metastasis, poor differentiation, and drug abuse. Our results provided evidence that TXNIP gene expression level is positively correlated with the overall survival of GC patients. Pan-cancer analysis of TCGA data revealed down-regulated TXNIP in a variety of malignant tumors. Conclusion. This study established low TXNIP expression as a prognostic biomarker in GC. It also revealed that the decrease in TXNIP expression likely favors metastatic GC. Practical Implications. Evaluation of TXNIP expression is informative in the prognosis of GC patients.
- 20 March 2014
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 34 (4) , 293-296
A comparative study on relieving post-episiotomy pain with diclofenac and indomethacin suppositories or placebo
In this study, we compare the prophylactic efficacy of a diclofenac suppository and an indomethacin suppository on decreasing post-episiotomy pain. A total of 90 women with 2nd-degree episiotomy were assigned to receive a single dose of diclofenac suppository (30), indomethacin suppository (30) or placebo (30), according to randomised blocks. The pain was assessed at 1, 2, 4, 6 and 12 hours after receiving analgesia, using the two methods of pain score and visual analogue. This study showed that in the group given diclofenac or indomethacin, at all the assessed hours, the pain measured was considerably less than in the suppository-free group (p < 0.05). Comparing the diclofenac and indomethacin groups, there were only significant differences in the 4 and 12 hour measurements: the diclofenac was more effective than the indomethacin (4th hour), but due to a shorter half-life, the diclofenac group in the 12th hour had more pain (p < 0.05). Diclofenac suppository is recommended at 4-hour intervals for all patients, without internal disorders, to decrease episiotomy pain.
- 20 March 2014
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 34 (4) , 293-296
A comparative study on relieving post-episiotomy pain with diclofenac and indomethacin suppositories or placebo
In this study, we compare the prophylactic efficacy of a diclofenac suppository and an indomethacin suppository on decreasing post-episiotomy pain. A total of 90 women with 2nd-degree episiotomy were assigned to receive a single dose of diclofenac suppository (30), indomethacin suppository (30) or placebo (30), according to randomised blocks. The pain was assessed at 1, 2, 4, 6 and 12 hours after receiving analgesia, using the two methods of pain score and visual analogue. This study showed that in the group given diclofenac or indomethacin, at all the assessed hours, the pain measured was considerably less than in the suppository-free group (p < 0.05). Comparing the diclofenac and indomethacin groups, there were only significant differences in the 4 and 12 hour measurements: the diclofenac was more effective than the indomethacin (4th hour), but due to a shorter half-life, the diclofenac group in the 12th hour had more pain (p < 0.05). Diclofenac suppository is recommended at 4-hour intervals for all patients, without internal disorders, to decrease episiotomy pain.